[CAS NO. 1129403-56-0] Amcasertib (BBI503)
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1129403-56-0]
Catalog
SLK-S8572
Brand
Selleck
CAS
1129403-56-0
DESCRIPTION [1129403-56-0]
Overview
| MDL | MFCD30489231 |
|---|---|
| Molecular Weight | 539.69 |
| Molecular Formula | C31H33N5O2S |
| SMILES | O=C(C1=C(C)NC(/C=C2C(NC3=C/2C=C(C4=CSC(C5=CC=CC=C5)=N4)C=C3)=O)=C1C)NCCN(CC)CC |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8529 mL | 9.2646 mL | 18.5292 mL |
| 5 mM | 0.3706 mL | 1.8529 mL | 3.7058 mL |
| 10 mM | 0.1853 mL | 0.9265 mL | 1.8529 mL |
| 50 mM | - | - | - |
Description
Amcasertib (BBI503), a first-in-class inhibitor, is claimed to inhibit and other CSC pathways by targeting kinases with potential anticancer activity.
Targets
| Nanog [1] |
In vitro
BBI-503 is orally-administered compound, which is designed to target CSC pathways in multiple tumour types.
In vivo
BBI503 inhibits Nanog and other cancer stem cell pathways by targeting kinases, and shows encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer.
Powered by Arctom Copyright © 2026 Arctom.
All rights reserved.